Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

CPD-Articles_23-46-Koji Takeuchi

http://benthamscience.com/journals/current-pharmaceutical-design/

Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

Kaja Blagotinšek

https://benthamscience.com/journals/current-pharmaceutical-design/

New Issue :: Current Pharmaceutical Design 23, Issue 5

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

CPD

Articles from the journal Current Pharmaceutical Design 23, Issue 5:


For details on the articles, please visit this link :: 
http://bit.ly/2nToM4R

 

 

SMi EVENT – BioBanking 2017!

SMi is delighted to announce its 7th Annual conference on BioBanking taking place in London, UK on the 14th and 15th of June 2017.

200X200

SMi’s 7th annual conference on Biobanking will bring together Europe’s leading biorepositories, regulatory representatives and scientific pioneers to strengthen knowledge in biosample management as well as explore future advances in areas such as mobile bio-banking and cloud based sample management. Understanding the ethical and regulatory framework as well as the impact of the General Data Protection Regulation (GDPR) on collaborative science in Europe will be a major focus. Plus, don’t miss keynote addresses from a selection of European biobanks currently adding value to clinical research through successful biobanking strategies including the European Sperm Bank, UK Biobank, UCL Baby Biobank, Auria Biobank and more.

Exclusive updates from the European Commission and NIBSC-MHRA, will be just some of the event highlights for 2017. Join us this June for innovative discussions through a series of interactive presentations, panel discussions and roundtables, and address relevant and critical issues on how to improve your biobanking practice.

For details visit the website at http://www.bio-banking-event.com/bentham or contact the team on Tel: +44 (0)20 7827 6000 / Email: events@smi-online.co.uk

Journal: Current Pharmaceutical Design

EBook: Frontiers in Drug Design & Discovery

Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

CPD-Articles_22-46-Jan Copeland

http://www.eurekaselect.com/606/journal/current-pharmaceutical-design

Podcast: Potential Application of 5-Aryl-Substituted 2-Amino- benzamide Type of HDAC1/2

Author(s): Shinichi Uesato, Yoshiyuki Hirata, Tsutomu Sasaki

For article details, visit: http://www.eurekaselect.com/148217

Subscribe our YouTube channelhttp://bit.ly/1lr0czy

Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

cpd-articles_23-rajaraman-eri

http://www.eurekaselect.com/606/journal/current-pharmaceutical-design

Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

cpb-articles_22-alexander-n-orekhov

http://www.eurekaselect.com/606/journal/current-pharmaceutical-design

Press Release for EurekAlert! Insulin resistance and polycystic ovary syndrome

Insulin resistance represents a major issue for people with polycystic ovary syndrome (PCOS), an endocrine disorder which is very common in young women, according to a new analysis of available data carried out by Dr. Paolo Moghetti, Associate Professor of Endocrinology at the University of Verona, Italy. His study reviewed information on epidemiology, pathogenesis, pathophysiology and treatment of the impaired insulin action frequently found in women with the condition. According to this analysis, insulin resistance appears to be a key mechanism in the pathogenesis of PCOS itself, primarily because hyperinsulinemia has a strict, probably bidirectional, interaction with androgen excess. Moreover, the impairment in insulin action is a central mechanism in the origin of metabolic abnormalities, which are also frequently found in these women and represent a major aspect underlying the medical burden attributed to PCOS. However, it is important to note that the risk of insulin resistance differs between clinical phenotypes of PCOS. Therefore, phenotyping of these women is helpful in defining their individual metabolic risk.

A fundamental question, which still remains unsolved, is why a large percentage of people with PCOS are insulin resistant. Most available data suggest that these women may have alterations in insulin action of heterogeneous origins, which induce specific abnormalities in these subjects due to the presence of intrinsic defects. Both genetic and acquired factors seem to be involved in this process. Body fat excess, which is another common feature of these women, may contribute to this phenomenon, combining with the effect of PCOS per se and worsening many clinical abnormalities typical of these subjects. In terms of treatment, insulin sensitization, by lifestyle changes and/or specific medications, is a strategy that shows several potential beneficial effects in this condition. However, treatment of these women must be personalized.

Reference: Moghetti, P.; (2016). Insulin Resistance and Polycystic Ovary Syndrome. Curr. Pharm. Des., DOI: 10.2174/1381612822666160720155855

For more information about the article, please link to: http://benthamscience.com/journals/current-pharmaceutical-design/article/144110/

 

Highlighted Article Flyer for the journal “Current Pharmaceutical Design”

cpd-articles_23-2017-zihang-pan

http://www.eurekaselect.com/606/journal/current-pharmaceutical-design